0001209191-19-029480.txt : 20190513 0001209191-19-029480.hdr.sgml : 20190513 20190513195246 ACCESSION NUMBER: 0001209191-19-029480 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190513 FILED AS OF DATE: 20190513 DATE AS OF CHANGE: 20190513 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Takeda Ventures, Inc. CENTRAL INDEX KEY: 0001771657 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38890 FILM NUMBER: 19820133 BUSINESS ADDRESS: STREET 1: 435 TASSO STREET STREET 2: SUITE 300 CITY: PALO ALTO STATE: CA ZIP: 94301 BUSINESS PHONE: 650-328-2900 MAIL ADDRESS: STREET 1: 435 TASSO STREET STREET 2: SUITE 300 CITY: PALO ALTO STATE: CA ZIP: 94301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: TAKEDA PHARMACEUTICAL CO LTD CENTRAL INDEX KEY: 0001395064 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38890 FILM NUMBER: 19820134 BUSINESS ADDRESS: STREET 1: 1-1, DOSCHOMACHI 4-CHOME CITY: CHUO-KU, OSALCA 540-8645 STATE: M0 ZIP: 00000 MAIL ADDRESS: STREET 1: 1-1, DOSCHOMACHI 4-CHOME CITY: CHUO-KU, OSALCA 540-8645 STATE: M0 ZIP: 00000 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Takeda Pharmaceuticals International AG CENTRAL INDEX KEY: 0001688140 STATE OF INCORPORATION: V8 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38890 FILM NUMBER: 19820135 BUSINESS ADDRESS: STREET 1: THURGAUERSTRASSE 130 STREET 2: GLATTPARK-OPFIKON CITY: ZURICH STATE: V8 ZIP: 8152 BUSINESS PHONE: 41-44-555-10-00 MAIL ADDRESS: STREET 1: THURGAUERSTRASSE 130 STREET 2: GLATTPARK-OPFIKON CITY: ZURICH STATE: V8 ZIP: 8152 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Takeda Pharmaceuticals U.S.A., Inc. CENTRAL INDEX KEY: 0001716229 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38890 FILM NUMBER: 19820136 BUSINESS ADDRESS: STREET 1: ONE TAKEDA PARKWAY CITY: DEERFIELD STATE: IL ZIP: 60015 BUSINESS PHONE: 2245546500 MAIL ADDRESS: STREET 1: ONE TAKEDA PARKWAY CITY: DEERFIELD STATE: IL ZIP: 60015 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cortexyme, Inc. CENTRAL INDEX KEY: 0001662774 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 269 EAST GRAND AVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-910-5717 MAIL ADDRESS: STREET 1: 269 EAST GRAND AVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-05-13 0 0001662774 Cortexyme, Inc. CRTX 0001771657 Takeda Ventures, Inc. 435 TASSO STREET, SUITE 300 PALO ALTO CA 94301 0 0 1 0 0001395064 TAKEDA PHARMACEUTICAL CO LTD 1-1, NIHONBASHI-HONCHO 2-CHOME CHUO-KU TOKYO M0 103-8668 JAPAN 0 0 1 0 0001688140 Takeda Pharmaceuticals International AG THURGAUERSTRASSE 130 8152 GLATTPARK-OPFIKON ZURICH 2M GERMANY 0 0 1 0 0001716229 Takeda Pharmaceuticals U.S.A., Inc. ONE TAKEDA PARKWAY DEERFIELD IL 60015 0 0 1 0 Common Stock 2019-05-13 4 C 0 2679802 A 2679802 D Series A Redeemable Convertible Preferred Stock 2019-05-13 4 C 0 2360071 0.00 D Common Stock 2360071 0 D Series B Redeemable Convertible Preferred Stock 2019-05-13 4 C 0 319731 0.00 D Common Stock 319731 0 D The total represents shares received upon conversion of shares of Series A Redeemable Convertible Preferred Stock and shares of Series B Redeemable Convertible Preferred Stock. Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date. These shares are owned directly by Takeda Ventures, Inc. Takeda Ventures, Inc. is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceuticals International AG owns 41.91% of Takeda USA, and Takeda Pharmaceutical Company Limited owns 58.09% of Takeda USA. Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited. /s/ Christopher Lowe, as Attorney-in-Fact for Takeda Ventures, Inc. 2019-05-13 /s/ Christopher Lowe, as Attorney-in-Fact for Takeda Pharmaceutical Company Limited 2019-05-13 /s/ Christopher Lowe, as Attorney-in-Fact for Takeda Pharmaceuticals International AG 2019-05-13 /s/ Christopher Lowe, as Attorney-in-Fact for Takeda Pharmaceuticals U.S.A., Inc. 2019-05-13